Clinical Trial

Targeted TDCS to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia.

Study acronym: AphasiatDCS
Recruiting
View on ClinicalTrials.gov →
Summary
62 patients who are one year post stroke and have Aphasia as a result of that stroke will be recruited. Participants will have 4 assessment sessions and 15 treatment sessions. The TDCS will be to right Inferior Frontal Gyrus (IFG) (25 active, 25 sham) for 15 days. A combined semantic feature analysis/phonological components analysis treatment will be paired with the stimulation. Two assessment sessions will be pretreatment, 1 session immediately post-treatment, and 1 session at 3 months follow-up.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2020-06-11; most recent amendment 2026-05-20.
Trial Details
NCT Number NCT04432883
Lead Sponsor University of New Mexico
Collaborators: National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS), National Institute on Deafness and Other Communication Disorders (NIDCD)
Conditions Stroke, Aphasia
Enrollment 50 participants
Start Date 2022-10-18
Primary Completion 2027-03-26 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22